The Effect of Creatine Monohydrate on Mental Disorders: A Systematic Review of Randomized Controlled Trials: Effet du monohydrate de créatine sur les troubles mentaux : examen systématique des essais contrôlés à répartition aléatoire
The Canadian Journal of Psychiatry · 2026-10 · 71 (10) · 741-751
DOI: 10.1177/07067437251408171 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift The Canadian Journal of Psychiatry, online erschienen am 20.01.2026. Verfasst von Bassam Jeryous Fares und 9 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Medicine, University of Ottawa, Ottawa, Canada. Hauptthemen laut MEDLINE: Creatine, Randomized Controlled Trials as Topic, Major Depressive Disorder, Bipolar Disorder. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Objective
The objective of this systematic review is to synthesize and evaluate the evidence involving creatine monohydrate supplementation (CrM) across mental disorders.
Methods
MEDLINE, Embase, Cochrane, and PsycINFO were searched up to 09/30/2025 for randomized controlled trials (RCTs) investigating the effect of CrM on psychiatric symptoms and safety in participants with a mental disorder. Risk of bias was assessed.
Results
Six articles from five RCTs were included (CrM: n = 126, placebo: n = 112; mean age=36 ± 14 years; male sex = 26%). Four RCTs reported on major depressive disorder (MDD), one bipolar depression. No other mental disorders were investigated. Two RCTs were low risk of bias and three had some concerns. CrM dosing ranged from 2 to 10 g/day for 4–8 weeks as adjunct treatment. In the treatment of MDD, CrM was tested as combination with escitalopram (k = 1, outperforming selective serotonin reuptake inhibitor (SSRI) + placebo; Cohen's d = 1.13 at 8 weeks), pharmacotherapy augmentation in adults (k = 1) and female adolescents (k = 1, no difference vs placebo), psychotherapy augmentation (k = 1, cognitive behavioural therapy (CBT) + CrM outperforming CBT + placebo) in MDD, and as pharmacotherapy augmentation in bipolar depression (k = 1, no difference vs placebo augmentation). Two trials in MDD found a correlation between CrM brain N-acetylaspartate and phosphocreatine, which was associated with larger improvement. CrM was generally well-tolerated. Two CrM out of 17 participants experienced hypomania/mania.
Conclusion
CrM shows promise as a combination treatment with SSRIs or for augmenting psychotherapy in MDD in adults. Double-blind, large-scale RCTs investigating the efficacy of CrM, with and without first-line therapies, are needed across mental disorders.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Faculty of Medicine, University of Ottawa, Ottawa, Canada.
- SCIENCES Lab, Department of Psychiatry, University of Ottawa, Ottawa, Canada.
- Department of Psychiatry, University of Toronto, Toronto, Canada.
- Department of Psychological Medicine, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK.
- Center for Sport Science and University Sports, University of Vienna, Wien, Austria.
- Learning Services, The Ottawa Hospital, Ottawa, Canada.
ORCID-Profile: Bassam Jeryous Fares, Carl Zhou, Nicholas Fabiano, Stanley Wong, Sergej M Ostojic
Zitieren
APA
Jeryous Fares, B., Zhou, C., Fabiano, N., Wong, S., Stubbs, B., Shorr, R., Puder, D., Candow, D. G., Ostojic, S. M., & Solmi, M. (2026). The Effect of Creatine Monohydrate on Mental Disorders: A Systematic Review of Randomized Controlled Trials: Effet du monohydrate de créatine sur les troubles mentaux : examen systématique des essais contrôlés à répartition aléatoire. The Canadian Journal of Psychiatry, 71(10), 741-751. https://doi.org/10.1177/07067437251408171
Vancouver
Jeryous Fares B, Zhou C, Fabiano N, Wong S, Stubbs B, Shorr R, et al. The Effect of Creatine Monohydrate on Mental Disorders: A Systematic Review of Randomized Controlled Trials: Effet du monohydrate de créatine sur les troubles mentaux : examen systématique des essais contrôlés à répartition aléatoire. The Canadian Journal of Psychiatry. 2026;71(10):741-751. doi:10.1177/07067437251408171
BibTeX
@article{JeryousFares2026,
author = {Jeryous Fares, Bassam and Zhou, Carl and Fabiano, Nicholas and Wong, Stanley and Stubbs, Brendon and Shorr, Risa and Puder, David and Candow, Darren G and Ostojic, Sergej M and Solmi, Marco},
title = {The Effect of Creatine Monohydrate on Mental Disorders: A Systematic Review of Randomized Controlled Trials: Effet du monohydrate de créatine sur les troubles mentaux : examen systématique des essais contrôlés à répartition aléatoire},
journal = {The Canadian Journal of Psychiatry},
year = {2026},
volume = {71},
number = {10},
pages = {741--751},
doi = {10.1177/07067437251408171}
}
EUVIMED